Cambrex Expands Process Research and Development Capabilities Across North America

- January 30th, 2018

Cambrex (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced an investment to expand chemical and analytical development capabilities at its Charles City, Iowa plant. As quoted in the press release: The expansion will see the construction of an additional 2,000 sq.ft. of laboratory space for development projects, … Continued

Cambrex (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced an investment to expand chemical and analytical development capabilities at its Charles City, Iowa plant.
As quoted in the press release:

The expansion will see the construction of an additional 2,000 sq.ft. of laboratory space for development projects, and will support the hiring of an additional 14 chemists. The building, installation and validation of equipment is expected to be completed by Q1 2018.

The expansion at Charles City is in parallel to the investments announced in 2017 at Cambrex’s facility in High Point, North Carolina, where a new 11,000 sq.ft. analytical laboratory and 400 sq.ft. pilot plant with a total reactor capacity of 4,000 liters are currently being completed. These expansions at High Point will create up to 18 new jobs.

Click here to read the full press release.

Read our FREE medical device report today

 

 

Get My Free Report  

Leave a Reply